Is the beta3-adrenoceptor (ADRB3) a potential target for uterorelaxant drugs?

The management of premature birth still remains unsatisfactory. Since the relative lack of efficiency and/or safety of current tocolytic agents have been highlighted, it is necessary to develop new uterorelaxant drugs deprived of important maternal and foetal side effects. Our work reported in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardou, Marc, Rouget, Céline, Breuiller-Fouché, Michèle, Loustalot, Catherine, Naline, Emmanuel, Sagot, Paul, Frydman, René, Morcillo, Esteban J, Advenier, Charles, Leroy, Marie-Josèphe, Morrison, John J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Proceedings
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892055/
https://www.ncbi.nlm.nih.gov/pubmed/17570158
http://dx.doi.org/10.1186/1471-2393-7-S1-S14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892055/
https://www.ncbi.nlm.nih.gov/pubmed/17570158
http://dx.doi.org/10.1186/1471-2393-7-S1-S14

Ejemplares similares